274 related articles for article (PubMed ID: 3489519)
1. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
2. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
3. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
4. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
5. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
6. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone S; Mutsuura S; Ogawara M; Tsubura E
J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
[TBL] [Abstract][Full Text] [Related]
7. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
[TBL] [Abstract][Full Text] [Related]
8. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
Maeda M; Asano T; Kleinerman ES
Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
[TBL] [Abstract][Full Text] [Related]
9. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.
Sone S; Utsugi T; Tandon P; Yanagawa H; Okubo A; Ogura T
Cancer Immunol Immunother; 1990; 30(6):357-62. PubMed ID: 2302725
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
11. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Shi F; MacEwen EG; Kurzman ID
Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs.
Shi F; Kurzman ID; MacEwen EG
Cancer Biother; 1995; 10(4):317-25. PubMed ID: 8590897
[TBL] [Abstract][Full Text] [Related]
14. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
15. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Fogler WE; Wade R; Brundish DE; Fidler IJ
J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
[TBL] [Abstract][Full Text] [Related]
16. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
[TBL] [Abstract][Full Text] [Related]
17. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES
Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931
[TBL] [Abstract][Full Text] [Related]
18. [Induction of tumoricidal properties in human monocytes by synergism between interferon-gamma and liposome-entrapped muramyl tripeptide].
Utsugi T; Sone S; Tandon P; Ogawara M; Shimizu E; Nii A; Nakanishi M; Shono M; Ogura T
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3161-8. PubMed ID: 3096216
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
Asano T; Kleinerman ES
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
20. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]